Categories
Blood Cancer

Latest updates in CAR-T therapy for follicular lymphoma [Video]

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of recent advances in CAR-T therapy for follicular lymphoma (FL). Axicabtagene ciloleucel (axi-cel) was the first CAR-T therapy to be approved in FL. The promising results of the ZUMA-5 (NCT03105336) and ELARA (NCT03568461) studies are expected to lead to the approval of tisagenlecleucel (tisa-cel) in relapsed/refractory (R/R) FL. Further longitudinal data is required to better understand the impact of CAR-T therapy in patients with FL, as well as to determine which patients are most likely to benefit from this immunotherapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Targeted therapy in CLL in 2022 and in the future [Video]

In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, gives an overview of her presentation at BSH 2022, which focused on targeted therapy in chronic lymphocytic leukemia (CLL) in 2022 and the future. Dr Eichhorst first discusses treatment options available to CLL patients, including continuous and time-limited approaches. Dr Eichhorst then highlights novel treatment regimens and clinical trials in CLL, including the FLAIR trial (ISRCTN01844152) investigating the use of ibrutinib in the frontline setting, and the benefit of combining venetoclax with obinutuzumab versus the use of fludarabine, cyclophosphamide and rituximab (FCR). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

Categories
Blood Cancer

Time-limited vs continued therapy in CLL treatment [Video]

In this video, Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, shares some insights into the use of time-limited therapy versus continued therapy in chronic lymphocytic leukemia (CLL). Dr Mato first explains the various treatment options available to patients, including Bruton’s tyrosine kinase (BTK) inhibitor monotherapy and combination therapy, as well as venetoclax plus obinutuzumab. Dr Mato then discusses the treatment options available to patients in the relapsed/refractory setting, including venetoclax plus rituximab and BTK inhibitors. Dr Mato concludes by explaining that there is no comparative data supporting one treatment regimen over the other, and that patient decisions vary depending on several factors, such as adverse event profile and presence of comorbidities. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Categories
Blood Cancer

Targeted therapy for the treatment of follicular lymphoma [Video]

Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, gives an overview on when to use targeted therapy in the treatment of follicular lymphoma (FL), highlighting several novel agents and trials investigating this. Dr Nastoupil first mentions some findings from the AUGMENT study (NCT01938001), which investigated the use of lenalidomide plus rituximab in relapsed/refractory (R/R) indolent lymphoma. Dr Nastoupil then draws focus on novel therapeutic agents such as tazemetostat, parsaclisib, CAR-T therapy, and bispecific antibodies, and the role that these will play in the future of targeted therapy for FL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

Categories
Blood Cancer

The influence of bridging therapy on outcomes in large B-cell lymphoma [Video]

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the use of bridging therapy in a real world setting for patients with large B-cell lymphoma (LBCL) receiving axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy. Stabilization of disease prior to treatment is associated with improved patients outcomes, independent of type of bridging therapy. However, investigational use of polatuzumab vedotin with rituximab and bendamustine as bridging therapy did not result in superior outcomes compared to other bridging regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GAIA/CLL13: Venetoclax-based time-limited combination therapies in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, gives an overview of the Phase III GAIA trial (NCT02950051), which assessed standard chemoimmunotherapy versus a combination of rituximab, venetoclax, obinutuzumab, and ibrutinib in patients with chronic lymphocytic leukemia (CLL). Patients received either standard chemoimmunotherapy, rituximab with venetoclax, obinutuzumab with venetoclax, or obinutuzumab with ibrutinib and venetoclax. Rituximab or obinutuzumab with venetoclax were associated with higher rates of undetectable minimal residual disease (uMRD), and whilst addition of ibrutinib added further benefit to patients, more adverse events were reported. Further research is required to identify patient subgroups who will benefit from chemoimmunotherapy the most. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Atezolizumab with R-GEMOX in patients with transformed DLBCL [Video]

Alex Herrera, MD, City of Hope, Duarte, CA, shares an update on the study evaluating the addition of the PD-L1 inhibitor, atezolizumab, to immunogenic chemoimmunotherapy, rituximab with gemcitabine and oxaliplatin (R-GEMOX) in patients with relapsed/refractory (R/R) transformed diffuse large b-cell lymphoma (DLBCL) or Richter transformation (RT) from chronic lymphocytic leukemia (CLL). While patients with RT did not show outstanding responses, the patients with transformed follicular lymphoma and transformed marginal zone lymphoma presented good response rates. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Tazemetostat and rituximab in r/r follicular lymphoma [Video]

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, comments on preliminary findings from a Phase II single-arm, open-label trial (NCT04762160) of tazemetostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, with rituximab in patients with relapsed/refractory follicular lymphoma (FL). Five patients have been enrolled so far and tazemetostat with rituximab have shown initial promise in patients, with further data yet to be published. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

RELEVANCE: Rituximab and lenalidomide in FL [Video]

Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares an overview of the phase III RELEVANCE trial (NCT01650701) of rituximab and lenalidomide (R2) versus rituximab-chemotherapy followed by rituximab maintenance in patients with high tumor burden, untreated follicular lymphoma (FL). Six years after initial treatment, both treatment arms demonstrated similar efficacy and survival, highlighting R2 as a viable chemotherapy-free treatment option. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.